Department of General Medical, Shaoxing People's Hospital (Shaoxing Hospital of Zhejiang University), Shaoxing, China.
Eur Rev Med Pharmacol Sci. 2017 Jul;21(3 Suppl):78-83.
We analyzed the impact of potent anti-hypertension or anti-thrombotic therapy after PCI in patients with coronary heart disease complicated with hypertension, whilst to reflect the prognosis by testing P-selectin.
A total of 177 patients with coronary heart disease (CHD) complicated with hypertension was continuously enrolled in this study and randomly divided into traditional anti-hypertension group (group A: 130/80 mm Hg ≤ BP ≤ 140/90 mm Hg; anti-hypertensive drugs: β blockers and angiotensin converting enzyme inhibitor, n=84) and potent anti-hypertension group (group B: BP <130/80 mm Hg; dosage and frequency in group B > group A, n=93). This study was approved by the Ethics Committee of Shaoxing People's Hospital. Signed written informed consents were obtained from all participants before the study. Patients who need a stent placed (CAG shows narrowed vascular diameter ≥75%) have to continuously be followed-up for one year. Standard anti-hypertension (fluctuation of BP <5 mm Hg measured for 3 successive days) was detected respectively at admission and inpatient. The blood pressure, low-density lipoprotein cholesterin (LDL-C), high-sensitivity C-reactive protein (hs-CRP) and P-selectin levels were tested 1 month and 1 year after discharge; the time of adverse events (AEs) was also recorded.
There were no statistical differences between the occurrence times of AEs between group A and B (p=0.946). The P-selectin [(83±21) vs. (69±16) μg/L, p=0.038], systolic pressure [(134±8) vs. (119±13) mm Hg, p<0.001] and diastolic pressure [(85±6) vs. (70±5) mm Hg] in group A were higher (p=0.001) than those of group B. Compared with P-selectin ≥50.00 μg/L, the median survival time (>12 vs. 10 months, χ2=3.621, p=0.047) of P-selectin <50.00 μg/L was longer. By comparing P-selectin in different SBP grading (<120 mm Hg, 120-130 mm Hg, 130-140 mm Hg), the difference was statistically significant (χ2=12.912, p=0.002).
Potent anti-hypertension may influence the occurrence time of AEs after PCI in patients with coronary heart disease complicated hypertension. P-selectin can be a sensitive indicator. SBP has an apparent "J-curve effect" and an appropriate anti-hypertensive scope (120-130 mm Hg).
我们分析了经皮冠状动脉介入治疗(PCI)后强效降压或抗栓治疗对合并高血压的冠心病患者的影响,并通过检测 P-选择素来反映预后。
连续纳入了 177 例合并高血压的冠心病患者(CHD),并将其随机分为传统降压组(A 组:血压 130/80mmHg≤BP≤140/90mmHg;降压药物:β受体阻滞剂和血管紧张素转换酶抑制剂,n=84)和强效降压组(B 组:BP<130/80mmHg;B 组的剂量和频率大于 A 组,n=93)。本研究经绍兴市人民医院伦理委员会批准。所有参与者在研究前均签署了书面知情同意书。需要置入支架的患者(CAG 显示血管直径狭窄≥75%)需要持续随访 1 年。分别在入院和住院期间检测标准降压(连续 3 天血压测量波动<5mmHg)。出院后 1 个月和 1 年检测血压、低密度脂蛋白胆固醇(LDL-C)、高敏 C 反应蛋白(hs-CRP)和 P-选择素水平;记录不良事件(AE)发生时间。
A 组和 B 组的 AE 发生次数无统计学差异(p=0.946)。A 组的 P-选择素[(83±21)vs.(69±16)μg/L,p=0.038]、收缩压[(134±8)vs.(119±13)mmHg,p<0.001]和舒张压[(85±6)vs.(70±5)mmHg]均高于 B 组(p=0.001)。与 P-选择素≥50.00μg/L 相比,P-选择素<50.00μg/L 的中位生存时间(>12 个月 vs. 10 个月,χ2=3.621,p=0.047)更长。比较不同收缩压分级(<120mmHg、120-130mmHg、130-140mmHg)的 P-选择素,差异有统计学意义(χ2=12.912,p=0.002)。
强效降压可能会影响合并高血压的冠心病患者 PCI 后 AE 的发生时间。P-选择素可能是一个敏感指标。收缩压有明显的“J 型曲线效应”,适当的降压范围(120-130mmHg)。